UK Biotech Co. Abcam Expands With $170M Epitomics Buy

Law360, New York (March 5, 2012, 1:15 PM EST) -- U.K. life sciences company Abcam PLC has agreed to spend $170 million to acquire U.S. company Epitomics International Inc., which provides antibodies to researchers, as part of a strategy to expand in China and around the world, Abcam announced Monday.

Abcam has entered into its largest-ever acquisition to take advantage of Epitomics' presence in China and to enhance its technology offerings as part of its ambition to become a leading biotechnology company, according to Abcam.

“These are exciting times for Abcam as we continue to source...
To view the full article, register now.